The Committee recognised that the available clinical data on the effectiveness of EXOGEN for treating long bone fractures with non-union show high rates of fracture healing and it judged them ...
Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE ...
The sponsor identified 3 economic studies, all in UK settings. Taylor et al. (2009) carried out a cost-effectiveness analysis on non-union tibial fractures treated by EXOGEN or by surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback